Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
IPO Year: 2019
Exchange: NASDAQ
Website: appliedtherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2024 | Outperform → Mkt Perform | William Blair | |
| 12/2/2024 | $13.00 → $2.00 | Buy → Neutral | UBS |
| 11/29/2024 | $12.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/31/2024 | Outperform | William Blair | |
| 3/26/2024 | $12.00 | Outperform | RBC Capital Mkts |
| 2/22/2024 | $12.00 | Outperform | Leerink Partners |
| 1/4/2022 | $44.00 → $7.00 | Overweight → Equal-Weight | Barclays |
| 8/27/2021 | $10.00 | Neutral → Sell | Goldman Sachs |
| 6/25/2021 | $18.00 | Neutral | Goldman |
4 - Applied Therapeutics Inc. (0001697532) (Issuer)